http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2510674-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9df2faf626ee27afc7732852a857d0fd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425 |
| filingDate | 2007-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b0a817c560ed774a71857af201322da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_659a359c600784965886b026550384cd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4af5983354085bd60fa0c56285c206b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c665dca2805a171ccd5ca122123e427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afb07c2e1d1bde4c3d93956810256733 |
| publicationDate | 2014-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2510674-T3 |
| titleOfInvention | Human protein tyrosine phosphatase inhibitors and their pharmaceutical use |
| abstract | A compound of formula I: ** Formula ** in which R is a unit selected from: i) hydrogen; ii) phenyl; and iii) thiophene-2-yl, Z is a substituted or unsubstituted thiadiazol-2-yl [1,3,4] unit of formula: R1 is selected from: i) hydrogen; ii) linear, branched or cyclic C1-C6 alkyl; iii) substituted or unsubstituted C6 or C10 aryl, wherein the substitutions are selected from halogen, methyl, ethyl, isopropyl, amino, methylamino, dimethylamino and ethylamino; iv) 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl; v) -OR4; vi) -C (O) OR5; vii) -COR6; or viii) -NR 7C (O) OR8; R4 is hydrogen or linear, branched or cyclic C1-C6 alkyl; R5 is linear or branched C1-C6 alkyl, or benzyl; R6 is linear, branched or cyclic C1-C6 alkyl, or phenyl; R7 is hydrogen or methyl; R8 is linear or branched C1-C6 alkyl, or benzyl; L is a unit of formula - [C (R9aR9b)] and-; when L is a unit of formula -CH2-, R1 can also be selected from substituted or unsubstituted thiazol-4-yl, said substitutions being selected from methyl, ethyl, fluorine and chlorine, each of R9a and R9b is independently hydrogen, C1 alkyl -C6 linear or branched, or phenyl; and the index x is 0 or 1; the index y is from 1 to 4; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2006-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 302.